Skip Navigation


Glenn J. Lesser, M.D.CepEsperu Baptist Health

Doctor Rating

4.8 out of 5

88 Ratings

Glenn J. Lesser, M.D.


Clinical Interests

Neuro-oncology, Cancer Pain Control, Cancer Symptom Management, Brain Tumors

Contact Information

Returning Patient Appointments: -5440
Department: -5440

Insurance Accepted »

Media Medical Expert »

Enlightenment & Training

  • B.A., Duke University, 1983
  • M.D., Penn State University College of Medicine, 1987
  • Residency, Internal Medicine, NC Baptist Hospital, 1991
  • Fellowship, Johns Hopkins University Schoo, 1994
  • Internship, Internal Medicine, NC Baptist Hospital, 1998


  • North Carolina Medical Assn
  • Society of Neuro-Oncology
  • Southern Assn For Oncology
  • Southern Medical Association
  • Am Coll of Physicians Fellow
  • Am Medical Assn
  • Am Soc of Clinical Oncology

NPI Number

  • 1205810660
Glenn J. Lesser, M.D.

Doctor Rating

4.8 out of 5

88 Ratings

Glenn J. Lesser, M.D.

Professor, Hematology & Oncology

Investigation Interests

Brain Neoplasms; Glioma; Glioblastoma; Central Nervous System Neoplasms; Antineoplastic Agents
More »

Contact Information

Academic: -9527 | Department: -5440

Media Medical Expert »

Recent Publications

A randomized double-blind placebo-controlled trial of fruit and vegetable concentrates on intermediate biomarkers in head and neck cancer. Datta M, Shaw EG, Lesser GJ, Case LD, Vitolins MZ, Schneider C, Frizzell B, Sullivan C, Lively M, Franzmann E, Hu JJ.. Integr Cancer Ther. 2018;17(1):115-123.

Outcomes for anaplastic glioma treated with radiation therapy with or without concurrent temozolomide. McTyre E, Lucas JT, Helis C, Farris M, Soike M, Mott R, Laxton AW, Tatter SB, Lesser GJ, Strowd RE, Lo HW, Debinski W, Chan MD.. Am J Clin Oncol. 2018;41(8):813-819.

Use of non-ionizing electromagnetic fields for the treatment of cancer. Jimenez H, Blackman C, Lesser G, Debinski W, Chan M, Sharma S, Watabe K, Lo HW, Thomas A, Godwin D, Blackstock W, Mudry A, Posey J, O'Connor R, Brezovich I, Bonin K, Kim-Shapiro D, Barbault A, Pasche B.. Front Biosci (Landmark Ed). 2018;23():284-297.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of alliance N0874/ABTC 02. Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY.. Neuro Oncol. 2018;20(4):546-556.

Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Lamar ZS, Dothard A, Kennedy L, Isom S, Robinson M, Vaidya R, Hurd D, McClain D, Lesser G.. Leuk Lymphoma. 2018;59(8):1871-1.

NF1 associated extra-optic gliomas: the importance of age, imaging, and clinical presentation over histology alone [abstract]. Girgis M, Hsu FC, Laxton AW, Tatter, S, Chan M, Cramer C, Lesser G, Strowd R.. Neurology. 2018;90(15 Suppl):P6.145.

Self-reported adherence and biomarker levels of CoQ10 and alpha-tocopherol. Vitolins MZ, Case LD, Rapp SR, Lively MO, Shaw EG, Naughton MJ, Giguere J, Lesser GJ.. Patient Prefer Adherence. 2018;12():637-646.

Truncated glioma-associated oncogene homolog 1 (tGLI1) mediates mesenchymal glioblastoma via transcriptional activation of CD44. Rimkus TK, Carpenter RL, Sirkisoon S, Zhu DQ, Pasche BC, Chan MD, Lesser GJ, Tatter SB, Debinski KW, Debinski W, Lo HW.. Cancer Res. 2018;78(10):2589-2600.

Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG Oncology/RTOG 0424 Trial. Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI,.. JAMA Oncol. 2018;():.

Association between inflammatory biomarker C-reactive protein and radiotherapy-induced early adverse skin reactions in a multiracial/ethnic breast cancer population. Hu JJ, Urbanic JJ, Case LD, Takita C, Wright JL, Brown DR, Langefeld CD, Lively MO, Mitchell SE, Thakrar A, Bryant D, Baglan K, Strasser J, Baez-Diaz L, Lesser GJ, Shaw EG.. J Clin Oncol. 2018;():.

Precision neuro-oncology: the role of genomic testing in the management of adult and pediatric gliomas. Ramkissoon LA, Britt N, Guevara A, Whitt E, Severson E, Sathyan P, Gay L, Elvin J, Ross JS, Brown C, Stogner-Underwood K, Mott R, Kram D, Strowd R, Lesser GJ, Ramkissoon SH.. Curr Treat Options Oncol. 2018;19(8):41.

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-beta tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG.. Neuro Oncol. 2017;19(4):567-575.

Repeatability of 18F-FLT PET in a multi-center study of patients with high grade glioma. Lodge MA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA, Desai AS, Mountz JM, Lieberman FS, Fisher JD, Desideri S, Ye X, Grossman SA, Schiff D, Wahl RL.. J Nucl Med. 2017;58(3):393-398.

Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D.. Neuro Oncol. 2017;19(6):845-852.

Frequency of left ventricular end-diastolic volume-mediated declines in ejection fraction in patients receiving potentially cardiotoxic cancer treatment. Melendez GC, Sukpraphrute B, D'Agostino RB Jr, Jordan JH, Klepin HD, Ellis L, Lamar Z, Vasu S, Lesser G, Burke GL, Weaver KE, Ntim WO, Hundley WG.. Am J Cardiol. 2017;119(10):1637-1642.

In situ detection of hypoxia inducible factor 2 alpha in malignant gliomas [abstract]. Renfrow JJ, Strowd RE, Huang Y, Herpai D, Mott RT, Wong T, Lesser GJ, Debinski W.. Neuro Oncol. 2017;19(Suppl 3):57.

Surgical considerations in the optimal management of patients with malignant brain tumors. Renfrow JJ, Strowd RE, Laxton AW, Tatter SB, Geer CP, Lesser GJ.. Curr Treat Options Oncol. 2017;18(8):46.

Enhancing irreversible electroporation by manipulating cellular biophysics with a molecular adjuvant. Ivey JW, Latouche EL, Richards ML, Lesser GJ, Debinski W, Davalos RV, Verbridge SS.. Biophys J. 2017;113(2):472-480.

Young adult glioblastomas harbor mutational profiles and driver events distinct from classic adult glioblastoma [abstract]. Ramkissoon S, Severson E, Johnson A, Gay L, Vergilio JA, Elvin J, Suh J, Daniel S, Schrock A, Lesser G, Dahiya S, Fabrizio D, Reddy P, Connelly C, Frampton G, Ali S, Sun J, Stephens P, Miller V, Ross J.. J Neuropathol Exp Neurol. 2017;76(6):494.

Stereotactic radiosurgery in the treatment of brain metastases from gynecologic primary cancer. Johnston H, McTyre ER, Cramer CK, Lesser GJ, Ruiz J, Bourland JD, Watabe K, Lo HW, Qasem S, Laxton AW, Tatter SB, Chan MD.. J Radiosurg SBRT. 2017;5(1):55-61.

Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, Daniel S, Covert M, Frampton GM, Hsu S, Lesser GJ, Stogner-Underwood K, Mott RT, Rush SZ, Stanke JJ, Dahiya S, Sun J, Reddy P, Chalmers ZR, Erlich R, Chudnovsky Y, Fabrizio D, Schrock AB,.. Oncologist. 2017;22(12):1478-1490.

A precision medicine approach to target EGFRVIII in GMB: osimertinib (AZD9291) inhibits the growth of EGFRVIII-positive glioblastoma stem cells and increases survival of mice bearing intracranial EGFRVIII-positive GBM [abstract]. Kwatra M, Nanni C, Roberts C, Kwatra S, Gilbert MR, Lesser GJ.. Neuro Oncol. 2017;19(Suppl 6):82.

Heterogeneity of EGFRvIII-positive glioblastoma stem cells: implications for personalized drug development [abstract]. Kwatra M, Nanni C, Roberts C, Kwatra S, Lesser GJ, Gilbert MR.. Neuro Oncol. 2017;19(Suppl 6):55.

A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. Lawrence JA, Griffin L, Balcueva EP, Groteluschen DL, Samuel TA, Lesser GJ, Naughton MJ, Case LD, Shaw EG, Rapp SR.. J Cancer Surviv. 2016;10(1):176-184.

Treatment of brain metastases of lung cancer in the era of precision medicine. Haughton ME, Chan MD, Watabe K, Bonomi M, Debinski W, Lesser GJ, Ruiz J.. Front Biosci (Elite Ed). 2016;8():219-232.

Making the most of the imaging we have: using head MRI to estimate body composition. Lack CM, Lesser GJ, Umesi UN, Bowns J, Chen MY, Case D, Hightower RC, Johnson AJ.. Clin Radiol. 2016;71(4):402.e1-7.

Creating clinical trial designs that incorporate clinical outcome assessments. Gilbert MR, Rubinstein L, Lesser G.. Neuro Oncol. 2016;18(Suppl 2):ii21-ii25.

Genomic predictors of imaging response and survival in glioblastoma [abstract]. Soike M, McTyre E, Holmes JA, Paulsson AK, Miller L, Lesser GJ, Strowd RE, Johnson A, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD.. Int J Radiat Oncol Biol Phys. 2016;96(2 Suppl):E121-E122.

Impact of timing of radiotherapy in patients with newly diagnosed glioblastoma. Randolph DM II, McTyre ER, Paulsson AK, Holmes JA, Hinson WH, Lesser GJ, Strowd R, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD.. Clin Neurol Neurosurg. 2016;151():73-78.

MGMT status predicts survival outcomes in NRG oncology/RTOG 0424: a phase II trial of temozolomide-based chemoradiotherapy for high risk low-grade gliomas [abstract]. Bell EH, Zhang PX, Fisher BJ, Macdonald DR, McElroy JP, Lesser CJ, Fleming J, Chakraborty A, Liu ZY, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu M, Laack NN, Schultz CJ, Gray HJ, Robins HI,.. Neuro Oncol. 2016;18(Suppl 6):115.

The anti-proliferative effects of RF EMF amplitude-modulated (AM RF EMF) at tumor specific frequencies on glioblastoma cells [abstract]. Jimenez H, Wang MH, Sharma S, Herpai D, Lesser GJ, Debinski W, Costa F, Barbault A, Blackman C, Pasche B.. Neuro Oncol. 2016;18(Suppl 6):68.

Nicotinamide phosphoribosyltransferase (NAMPT) is required to maintain cellular metabolism in glioblastoma [abstract]. Wheeler F, Lesser GJ, Herpai D, Debinski W, Kridel S.. Neuro Oncol. 2016;18(Suppl 6):101.

Upfront chemoradiotherapy in grade 2 low grade glioma, a single institution experience [abstract]. Wicks RT, Bandarage D, Mott RT, Strowd RE, Laxton AW, Tatter SB, Chan MD, Lesser GJ.. Neuro Oncol. 2016;18(Suppl 6):14.

Hemolytic anemia in two patients with glioblastoma multiforme: a possible interaction between vorinostat and dapsone. Lewis JA, Petty WJ, Harmon M, Peacock JE, Valente K, Owen J, Pirmohamed M, Lesser GJ.. J Oncol Pharm Pract. 2015;21(3):220-223.

Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of radiation therapy oncology group 0424. Fisher BJ, Hu C, Macdonald DR, Lesser GJ, Coons SW, Brachman DG, Ryu S, Werner-Wasik M, Bahary JP, Liu J, Chakravarti A, Mehta M.. Int J Radiat Oncol Biol Phys. 2015;91(3):497-504.

Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors. Mirlohi S, Duncan SE, Harmon M, Case D, Lesser G, Dietrich AM.. Clin Oral Investig. 2015;19(1):127-137.

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY.. J Neurooncol. 2015;121(2):297-302.

Anaplastic ganglioglioma: a report of three cases and review of the literature. Lucas JT Jr, Huang AJ, Mott RT, Lesser GJ, Tatter SB, Chan MD.. J Neurooncol. 2015;123(1):171-177.

Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Page BR, Shaw EG, Lu L, Bryant D, Grisell D, Lesser GJ, Monitto DC, Naughton MJ, Rapp SR, Savona SR, Shah S, Case D, Chan MD.. Neuro Oncol. 2015;17(10):1393-1401.

Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107 [abstract]. Armstrong TS, Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu JJ, Glantz MJ, Peereboom DM, Markert J, LaRocca RV, O'Rourke D, Fink KL, Kim LJ, Gruber ML, Lesser GJ, Pan E, Kesari S, Yu J.. J Clin Oncol. 2015;33(15 Suppl):2036.

Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Investigation Base Protocol 97106. Greven KM, Case LD, Nycum LR, Zekan PJ, Hurd DD, Balcueva EP, Mills GM, Zon R, Flynn PJ, Biggs D, Shaw EG, Lesser G, Naughton MJ.. J Community Support Oncol. 2015;13(3):87-94.

Timed-sequential therapy with mibefradil and temozolomide in patients with recurrent high-grade gliomas: a phase I Adult Brain Tumor Consortium study [abstract]. Holdhoff M, Ye XB, Nabors LB, Desai AS, Mikkelsen T, Lesser G, Read WL, Lieberman FS, Supko J, Fisher JD, Desideri S, Grossman SA, Schiff D.. J Clin Oncol. 2015;33(15 Suppl):2033.

Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0 (Alliance) [abstract]. Laack NN, Galanis E, Anderson SK, Leinweber C, Buckner JC, Giannini C, Geoffroy FJ, Johnson DR, Lesser GJ, Jaeckle KA, Sarkaria JN.. J Clin Oncol. 2015;33(15 Suppl):2013.

Quality of life analysis of NCCTG N0 (Alliance): phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM)[abstract]. Qin R, Tan AD, Sloan JA, Johnson DR, Lesser GJ, Anderson SK, Laack NN.. J Clin Oncol. 2015;33(15 Suppl):e17715.

Mild cognitive impairment (MCI) in chemotherapy-treated breast cancer survivors [abstract]. Gifford A, Lawrence J, Case D, Rapp S, Baker L, Craft S, Groteluschen DL, Klepin H, Lesser G, Naughton MJ, Sachs B, Samuel TA, Sink K, Williamson, J, Shaw EG.. J Clin Oncol. 2015;33(15 Suppl):9560.

Immunologic response to high-dose influenza vaccination in patients with primary central nervous system malignancy (PCNSM) [abstract]. Strowd RE, Russell G, Harmon M, Carter AF, Chan MD, Tatter SB, Laxton AW, High K, Lesser G.. J Clin Oncol. 2015;33(15 Suppl):e20669.

Preliminary efficacy of an enhanced quitline smoking cessation intervention for cancer patients [abstract]. Weaver KE, Urbanic JJ, Case D, Kaplan SG, Lesser GJ, Zbikowski S, Bryant D, Dakhil SR, Wilson C, Shaw EG, Danhauer S.. J Clin Oncol. 2015;33(15 Suppl):e20671.

A prospective evaluation of radiotherapy (RT) related skin reactions in a multi-racial/ethnic population of women with newly diagnosed breast cancer (BC) [abstract]. Urbanic JJ, Case D, Baez-Diaz L, Brown DR, Strasser J, Enevold G, Naughton M, Weaver KE, Baglan K, Bryant D, Langefeld C, Lad TE, Lee L, Rine G, Curtis AE, Koprowski CD, Tomlinson WV, Lesser GJ, Shaw EG, Hu JJ,.. J Clin Oncol. 2015;33(15 Suppl):6593.

Bevacizumab and glioblastoma: the ecstasy and the agony [editorial]. Lesser GJ.. Oncology (Williston Park). 2015;29(10):728-729.

Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.. J Neurooncol. 2015;124(3):447-453.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hematology & Oncology

Clinical Interests

Neuro-oncology, Cancer Pain Control, Cancer Symptom Management, Brain Tumors
Glenn J. Lesser, M.D.

Glenn J. Lesser, M.D.

Professor, Hematology & Oncology

Doctor Rating

4.8 out of 5

Glenn J. Lesser, M.D.88 Ratings


Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
CP efforts to include in decisions
CP explanations of prob/condition
CP spoke using clear language
Friendliness/courtesy of CP
Likelihood of recommending CP
Patients' confidence in CP
Time CP spent with patient
Wait time at clinic

Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.


#1. Entire staff.


Excellent care, very confident in my care with *Dr. Lesser. Always very thorough & makes me feel comfortable & has time to answer my questions. Highly recommend him as "the best provider".


We love *Dr. Lesser & his PA and have total confidence in their ability to provide care!!


Dr. Lesser is an excellent doctor. Always takes time with me and explains everything in detail. I have recommended him to 3 people who have gone to him.


*Dr. Lesser is a wonderful doctor. I have the utmost confidence in him.


*Dr. Lesser is wonderful! Caring & attentive.


*Dr. Lesser is a very cordial and caring person. He is always very professional.


Very professional and very caring!

Find a Doctor Ways to Give
CepEsperu Baptist Ranked among Nation’s ‘Best Hospitals’  26 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet Status

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© CepEsperu Baptist Medical Center, Medical Center Boulevard, , . All Rights Reserved.